Early, efficient detection and treatment of rheumatoid arthritis using new delivery system

June 9, 2016, European League Against Rheumatism

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that tiny particles made of a biodegradable polymer (BNPs—biodegradable polymer nanoparticles) have the potential to enable early detection and efficient long-term treatment of rheumatoid arthritis (RA), with minimal side effects. By coating these particles with a peptide that is only able to target inflamed joint tissue, BNPs may be used to efficiently and selectively deliver drugs and diagnostic probes into arthritic joints.

"Despite dramatic advances in the treatment of RA, currently available therapies can cause several , many patients fail to respond, and true remission is only achieved in a minority," said Dr Paolo Macor lead investigator from the Department of Life Sciences, University of Trieste, Italy. "This is often due to late diagnosis of the pathology," he added.

"There is therefore a need to develop a new tool to enable , and also to develop tissue-specific agents able to reduce systemic side effects. This would increase the potency of the drug with lower doses, and also potentially reduce the cost of treatment," Dr Macor explained.

Unlike conventional drugs, BNPs can be designed to deliver specifically to the site of inflammation. They also allow investigators to consider or reconsider therapeutic agents that were previously deemed too toxic to deliver through a systemic route. BNPs can also be filled with a contrast agent, such as gadolinium, and then used as a diagnostic tool for an early and functional diagnosis of joint inflammation. Early diagnosis and therapy has been identified as a potentially crucial step in achieving optimal control of disease progression and prognosis in RA.

Using an immunofluorescence technique, these peptide-coated BNPs were shown to preferentially target inflamed joint tissue. A single injection of targeted BNPs loaded with methotrexate completely resolved inflammation in a rat model of antigen-induced arthritis, while the same dose of free-methotrexate injected into the rat's bloodstream was ineffective.

Using a mouse model of chronic collagen-induced arthritis, an equivalent therapeutic effect was obtained comparing methotrexate-loaded BNPs and the same dose of free methotrexate with no toxic effects.

"The advantage of being able to deliver methotrexate in this targeted way is to be able to gain the benefits from this key treatment of RA, while reducing the risk of adverse effects that are more frequent at high doses," concluded Dr Macor.

Explore further: New approach to arthritis treatment could avoid serious side-effects

Related Stories

New approach to arthritis treatment could avoid serious side-effects

September 19, 2014
(Medical Xpress)—A new approach to arthritis treatment, which avoids unforeseen side-effects by delivering drugs exclusively to affected inflamed joints, has been developed by researchers at Queen Mary University of London.

Prednisone use linked to increased risk of mortality in RA

May 27, 2016
(HealthDay)—For patients with rheumatoid arthritis (RA), prednisone use is associated with an increased risk of mortality, according to a study published in the May issue of Arthritis Care & Research.

Intensive initial therapy with triple DMARDs improves functional ability in early RA

June 10, 2015
The results of the tREACH trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that initial therapy with combination DMARDs significantly improves measures of ...

Chinese herbal remedy as good as methotrexate for treating rheumatoid arthritis

April 14, 2014
A traditional Chinese herbal remedy used to relieve joint pain and inflammation works as well as methotrexate, a standard drug treatment that is frequently prescribed to control the symptoms of active rheumatoid arthritis, ...

Methotrexate exposure impacts cognitive processes cancer survivors need to multitask

June 6, 2016
Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the chemotherapy drug methotrexate are more likely to struggle with mental flexibility, organization ...

Rheumatism treatment effective even when the use of biological agents is slightly delayed

December 5, 2013
The immediate use of a biological agent associated with more side effects and higher costs in the treatment of rheumatoid arthritis yields no better results than a less aggressive plan with the delayed use of biological agents ...

Recommended for you

Dietary carbohydrates could lead to osteoarthritis, new study finds

August 9, 2018
Do your knees ache? According to new findings from the Oklahoma Medical Research Foundation, your diet could be a culprit.

Joint study raises questions about treatments for arthritis

August 3, 2018
A study examining how molecules are transported into knee-joint tissue could have major implications for understanding and treating arthritis.

Researchers identify new arthritis severity gene

July 26, 2018
A new gene associated with disease severity in models of rheumatoid arthritis has been identified by researchers at the Icahn School of Medicine at Mount Sinai. The discovery could provide a new pathway for treatment and ...

How the brain plays a role in rheumatoid arthritis inflammation

June 18, 2018
In patients with chronic inflammatory conditions, such as rheumatoid arthritis, there has been limited understanding of how this inflammation affects the brain.

New 3-D imaging analysis technique could lead to improved arthritis treatment

June 18, 2018
An algorithm to monitor the joints of patients with arthritis, which could change the way that the severity of the condition is assessed, has been developed by a team of engineers, physicians and radiologists led by the University ...

Joint resolution: A link between Huntington's disease and rheumatoid arthritis

May 15, 2018
Using new analytic tools, researchers at University of California San Diego School of Medicine and the Icahn School of Medicine at Mount Sinai have decoded the epigenetic landscape for rheumatoid arthritis (RA), a common ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.